EP 3 389 691 B1 relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). It also relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection.